Please try another search
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
Name | Age | Since | Title |
---|---|---|---|
Koichi Murakami | 64 | 2021 | GM of Corporate Planning Management Department & Director |
Kiichi Adachi | - | 2005 | President & Director |
Masahiro Motokawa | - | 2018 | Audit & Supervisory Board Member |
Yosuke Yamaguchi | - | 2018 | Audit & Supervisory Board Member |
Daichika Hayata | - | 2022 | GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director |
Masato Fukui | 48 | 2020 | Independent Outside Director |
Kohichiro Yoshino | 75 | 2018 | Independent Outside Director |
Akihiro Tomoyasu | 54 | 2016 | Part Time Director |
Kazuto Ninomiya | 71 | 2018 | Audit & Supervisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review